Afuresertib

Drug Overview

Afuresertib is an advanced, experimental cancer medicine. It belongs to a modern group of treatments known as “Targeted Therapies” or “Smart Drugs.” Instead of attacking all the fast-growing cells in the body like traditional chemotherapy does, targeted therapies are designed to find and block specific broken parts inside cancer cells.

Right now, afuresertib is not available at a regular pharmacy. It is an investigational drug, meaning it is currently being studied in clinical trials at major research hospitals. Doctors are testing it to see how well it fights several types of difficult-to-treat cancers, such as prostate cancer, ovarian cancer, and multiple myeloma.

• Generic Name: Afuresertib
• US Brand Names: None (Currently an investigational drug)
• Drug Class: AKT Kinase Inhibitor / Targeted Therapy
• Route of Administration: Oral (Capsule or Tablet)
• FDA Approval Status: Not FDA Approved. It is actively being studied in Phase I and Phase II clinical trials.

What Is It and How Does It Work? (Mechanism of Action)

To understand how afuresertib works, we have to look closely at the molecular command centers inside our cells.

Inside human cells, there is a communication network called the PI3K/AKT/mTOR signaling pathway. You can think of this pathway as a set of traffic lights that tells the cell when to grow, divide, and survive. In many types of cancer, these traffic lights are broken and stuck on “green.” This causes the cancer cells to multiply out of control and refuse to die when they should.

The key protein keeping this green light on is named AKT (also known as protein kinase B). Afuresertib is specifically designed to hunt down and attach itself to this AKT protein. By binding to AKT, the drug blocks it from doing its job. This successfully turns the traffic light red. Without the constant signal to grow and survive, the cancer cells stop dividing and eventually trigger their own natural death (a process scientists call apoptosis).

FDA Approved Clinical Indications

Important Note: Because afuresertib is an experimental medication, it does not currently have any official FDA approvals for general public use. However, it is being actively tested in clinical trials for the following investigational oncological uses:

• Treatment of metastatic castration-resistant prostate cancer (often in combination with other hormone-blocking drugs).
• Treatment of advanced ovarian cancer (often combined with chemotherapy).
• Treatment of multiple myeloma (a type of blood cancer) that has not responded to other treatments.

Non-oncological uses:

• None. This drug is strictly being studied for cancer treatment.

Dosage and Administration Protocols

Because afuresertib is an investigational drug, the exact dosage is decided by strict clinical trial rules. The information below reflects the general dosing protocols used in early clinical studies.

Dose Adjustments

• Renal/Hepatic Insufficiency: Because the drug is still being studied, standard dose adjustments for people with kidney or liver disease are not fully established. In clinical trials, doctors closely check a patient’s liver and kidneys. If there are signs of mild to moderate organ stress, the trial doctor may lower the daily dose (for example, to 100 mg or 75 mg) or pause the treatment temporarily.

Clinical Efficacy and Research Results

Recent clinical research between 2020 and 2025 has focused on using afuresertib together with other cancer-fighting drugs. Because cancers are smart, they often find ways around a single targeted drug.

• Combination Success: Recent Phase II trials have tested afuresertib combined with hormone therapies (like LAE001) for advanced prostate cancer. Early results show that this combination helps shrink tumors and lower PSA levels (a prostate cancer marker) better than using hormone therapy alone.
• Disease Progression: In heavily pre-treated patients with ovarian cancer, early studies showed that combining afuresertib with standard chemotherapy (paclitaxel) helped delay the cancer from growing (improved Progression-Free Survival) compared to patients who only received chemotherapy.
• Current Status: Researchers are currently using these promising early response rates to build larger Phase III trials. These future trials will provide exact numerical data on long-term survival rates.

Safety Profile and Side Effects

Like all targeted therapies, blocking the AKT pathway can affect healthy cells that also use this pathway, leading to specific side effects.

Black Box Warning

There is no FDA Black Box Warning for afuresertib, as it is still in the investigational phase.

Common Side Effects (Occur in >10% of patients)

• Hyperglycemia (High Blood Sugar): The AKT pathway helps the body process insulin. Blocking it often causes blood sugar levels to rise.
• Gastrointestinal Issues: Nausea, vomiting, and diarrhea.
• Fatigue: Feeling unusually tired or weak.
• Skin Rash: Red, itchy breakouts on the skin.
• Decreased Appetite.

Serious Adverse Events (Occur rarely)

• Severe Hyperglycemia: Dangerously high blood sugar that may require insulin treatment.
• Severe Diarrhea: Leading to extreme dehydration and kidney strain.
• Liver Enzyme Elevation: Signs of inflammation in the liver.

Side Effect Management Strategies

• For High Blood Sugar: Doctors will check your blood sugar often. Patients may need to change their diet or start taking diabetes medications (like metformin) while on the trial.
• For Diarrhea: Keep over-the-counter anti-diarrhea medicine on hand and drink plenty of water. Report severe diarrhea to the trial doctor immediately.
• For Skin Rashes: Use gentle, unscented lotions and avoid long exposure to the sun.

Research Areas

Afuresertib is a major focus in the research area of overcoming drug resistance. Many cancers eventually become resistant to standard chemotherapies or hormone therapies by activating the PI3K/AKT pathway. Scientists are actively testing afuresertib as a “combo-drug” to block this escape route. There is currently no significant research linking this specific drug to stem cell therapies or regenerative medicine, as its primary role is to stop cancer cell growth.

Patient Management and Practical Recommendations

Pre-Treatment Tests to be Performed

• Blood Sugar Testing: A fasting blood glucose test and an HbA1c test must be done to check for hidden diabetes before starting the drug.
• Liver and Kidney Panels: Blood tests to ensure the organs are healthy enough for a clinical trial.
• Heart Check (ECG): To ensure the electrical activity of the heart is normal.

Precautions During Treatment

• Dietary Monitoring: Because this drug can raise blood sugar, patients should be careful with eating too many sugary foods or simple carbohydrates.

Do’s and Don’ts

• DO ask your oncologist if you qualify for a clinical trial testing afuresertib if you have advanced prostate, ovarian, or blood cancer.
• DO check your blood sugar at home if your trial doctor gives you a glucose monitor.
• DO swallow the capsules whole with a glass of water. Do not chew or crush them.
• DON’T start any new vitamins, herbal supplements, or other medications without telling your clinical trial team, as they might interact with the experimental drug.
• DON’T ignore signs of high blood sugar, such as feeling very thirsty, needing to pee often, or having blurred vision.

Legal Disclaimer

The information provided in this guide is for educational and informational purposes only and does not constitute medical advice. It should not be used to diagnose, treat, cure, or prevent any disease or health condition. Always consult with a qualified healthcare professional or your treating oncologist regarding specific medical concerns, clinical trial eligibility, treatment options, or before starting, stopping, or altering any medication regimen. Every patient’s medical situation is unique, and therapies should be customized by a licensed physician.